# iTeos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iteos-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.iteostherapeutics.com
- Total disclosed funding: $206M
- Latest round: Series B (Mar 24, 2020)
- Investors on record: 16

## About

Founded in 2013 and based in Massachusetts, US, iTeos Therapeutics Inc., operates as a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics for cancer patients. In March 2020, Iteos Therapeutics S.A. raised USD 125.36 million in series B funding co-led by investors Boxer Capital and RA Capital, with participation from Invus, Janus Henderson Investors, and RTW Investments. As of 2023, the company is led by its President, and Chief Executive Officer, Michel Detheux, and has partnered with companies like Ludwig Cancer Research, Oncode Institute, UCLouvain, and many more. The company operates in locations like Watertown, Massachusetts, Gosselies, and Belgium. The company is listed on Nasdaq Stock exchange under ticker symbol, ITOS. iTeos Therapeutics offers various immunotherapy solutions by targeting immunometabolism and immunosuppressive cells in the tumour's microenvironment. The company’s pipelined products include Inupadenant, an A2A receptor antagonist, and EOS-448, used as a treatment for solid tumours in monotherapy and as an anti-TIGIT antibody antagonist in patients with cancer. In May 2024, iTeos Therapeutics Inc. raised USD 120 million in PIPE funding co-led by Boxer Capital and RA Capital Management. As part of the transaction, the company agreed to sell 1.14 million shares of common stock and pre-funded warrants to purchase 5.71 million shares of common stock for USD 120 million at USD 17.50 per share.

## Funding rounds

- Series B, Mar 24, 2020, $125M — HBM Partners, Vives, Invus [DUP], MPM BioImpact, SFPI-FPIM, RTW Investments, RA Capital Management, 6 Dimensions Capital, Boxer Capital, Fund+, SRIW, Janus Henderson Investors, Curative Ventures
- Series B, Apr 24, 2019, $1.8M — HBM Partners
- Series B, Jun 20, 2018, $75M — HBM Partners, Vives, MPM BioImpact, SFPI-FPIM, 6 Dimensions Capital, Fund+, SRIW, Curative Ventures
- Series A, May 3, 2012, $3.9M — Ludwig Institute for Cancer Research Fund, Vives, Hunza Ventures, Life Sciences Research Partners

## Investors

- Ludwig Institute for Cancer Research Fund — Series A
- Vives (https://capitalatlas.ai/funds/vives) — Series A, Series B
- Hunza Ventures (https://capitalatlas.ai/funds/hunza-ventures) — Series A
- Life Sciences Research Partners — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B
- SFPI-FPIM — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- Fund+ (https://capitalatlas.ai/funds/fund) — Series B
- SRIW — Series B
- Curative Ventures (https://capitalatlas.ai/funds/curative-ventures) — Series B
- Invus [DUP] — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Janus Henderson Investors — Series B